A multi-centre Phase IIa double-blind, placebo-controlled study to investigate the efficacy and safety of GSK3196165 in subjects with inflammatory hand osteoarthritis.
Phase of Trial: Phase II
Latest Information Update: 02 May 2018
At a glance
- Drugs Otilimab (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 02 May 2018 According to a MorphoSys media release, data publication anticipated in 2018.
- 12 Dec 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 Planned End Date changed from 6 Dec 2017 to 29 Nov 2017.